{"entity":{"id":"nct06921928","kind":"trial","name":"Study for AZD4360 in Participants With Advanced Solid Tumours","aka":[],"tldr":"A phase 1/2 trial of AZD4360 in pancreatic ductal adenocarcinoma, run by AstraZeneca, active and no longer recruiting.","summary":"Study for AZD4360 in Participants With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06921928 by AstraZeneca, with 31 participants enrolled, started 2025-04-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: AZD4360. Conditions listed: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06921928","url":"https://clinicaltrials.gov/study/NCT06921928"}],"tags":["ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["azd4360"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06921928","phase":"1/2","setting":"A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours","sponsor":"AstraZeneca","enrolled":31,"outcomes":[]},"route":"/trials/nct06921928/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"azd4360","kind":"drug","name":"AZD4360","route":"/drugs/azd4360/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}